CTRV - ContraVir Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
8.89
-1.22 (-12.07%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close10.11
Open8.87
Bid8.84 x 900
Ask9.31 x 1200
Day's Range8.62 - 10.66
52 Week Range4.80 - 117.60
Volume468,535
Avg. Volume334,378
Market Cap5.249M
Beta (3Y Monthly)0.28
PE Ratio (TTM)N/A
EPS (TTM)-81.89
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.00
Trade prices are not sourced from all markets
  • Benzinga5 days ago

    Why Low-Float, Thinly Traded ContraVir Pharma's Rally Is Continuing

    June has been an eventful month for  ContraVir Pharmaceuticals Inc (NASDAQ: CTRV ). Close on the heels of a 1-for-70 reverse stock split, which became effective June 3, the company has had incremental ...

  • GlobeNewswire5 days ago

    ContraVir Pharmaceuticals Announces Publication of CRV431 Data from Experimental Model of Hepatitis B

    EDISON, N.J., June 11, 2019 -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of.

  • Why ContraVir Pharmaceuticals (CTRV) Is Skyrocketing Today
    InvestorPlace9 days ago

    Why ContraVir Pharmaceuticals (CTRV) Is Skyrocketing Today

    ContraVir Pharmaceuticals (NASDAQ:CTRV) had a memorable Friday as the company's stock soared off the heels of a successful results regarding one of its treatments for liver disease.Source: Shutterstock The Edison, New Jersey-based pharmaceutical business today unveiled findings from a preclinical study in which CRV431, which is a novel cyclophilin inhibitor, significantly helped to decrease the extent of fibrosis in a second animal model of liver fibrosis. The term fibrosis refers to scarring of the liver, and it is a common symptom of non-alcoholic steatohepatitis (NASH), which causes impaired liver function.ContraVir Pharmaceuticals focuses mostly on developing therapeutic drugs to treat liver disease that arises from NASH. The company said that obeticholic acid (OCA), which is a semi-synthetic bile acid analogue drug, was approved for the treatment of primary biliary cholangitis (PBC), and it is being evaluated in Phase 3 trials by another company.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe medication was used by a comparator drug within the study and did not decrease the extent of fibrosis in this study conducted by the company. This industry-standard model requires liver fibrosis to be induced in mice by administering carbon tetrachloride."This is the second animal model, and the fifth study overall, in which CRV431 consistently demonstrated a statistically significant reduction in fibrosis," said Dr. Robert Foster, Chief Executive Officer of ContraVir. "In addition, this study showed that CRV431 reduced fibrosis where OCA, a drug approved for PBC with potential to treat additional liver diseases, such as NASH, did not." More From InvestorPlace * 10 Stocks to Buy That Could Be Takeover Targets * 7 S&P 500 Stocks to Buy That Tore Up Earnings * The 10 Best Stocks for 2019 -- So Far Compare Brokers The post Why ContraVir Pharmaceuticals (CTRV) Is Skyrocketing Today appeared first on InvestorPlace.

  • Benzinga10 days ago

    ContraVir Rallies As NASH Drug Shows Efficacy In Preclinical Study

    Shares of the nano-cap, thinly traded biotech  ContraVir Pharmaceuticals Inc (NASDAQ: CTRV ) were trading nearly 150-percent higher Thursday.  What Happened ContraVir, which focuses on therapies for liver ...

  • GlobeNewswire10 days ago

    ContraVir Pharmaceuticals Sets the Stage for CRV431 Development in NASH with Positive Results from Second Model of Liver Fibrosis

    ContraVir Pharmaceuticals, Inc. (CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”) and chronic viral infection, today announced findings from a preclinical study where CRV431, a novel cyclophilin inhibitor, significantly decreased the extent of fibrosis in a second animal model of liver fibrosis. Fibrosis, or scarring, of the liver is a hallmark symptom of NASH that results in impaired liver function.

  • GlobeNewswire16 days ago

    ContraVir Pharmaceuticals, Inc. Announces Reverse Stock Split

    ContraVir Pharmaceuticals, Inc. (Nasdaq: CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic viral infection, announced today a reverse split of its common stock, $0.0001 par value, at a ratio of 1 for 70 effective May 31, 2019 (the “Effective Date”). The reverse stock split is primarily intended to bring the Company into compliance with the minimum bid price requirement for maintaining its listing on the Nasdaq Capital Market.

  • GlobeNewswirelast month

    ContraVir Pharmaceuticals Receives Positive Nasdaq Listing Decision

    ContraVir Pharmaceuticals, Inc. (Nasdaq: CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic viral infection, announced today that the Nasdaq Hearings Panel has granted the Company’s request for continued listing on The Nasdaq Capital Market, subject to compliance with certain conditions. The Company is diligently working to evidence full compliance with all applicable requirements for continued listing on The Nasdaq Capital Market, in particular the $1.00 minimum bid price requirement.

  • GlobeNewswire2 months ago

    ContraVir Pharmaceuticals to Present at the 2019 ThinkEquity Conference

    ContraVir Pharmaceuticals, Inc. (CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic viral infection, today announced that management will present an update on the Company’s business at the 2019 ThinkEquity Conference on Thursday, May 2, 2019 at 1:30 p.m. Eastern Time in New York, NY. ContraVir is a clinical stage biopharmaceutical company focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic hepatitis virus infection (HBV, HCV, HDV).

  • Benzinga2 months ago

    The Daily Biotech Pulse: Mixed Results For Merck's Keytruda In Stomach Cancer; Roche's Spark-Buy Delayed, Teva Recalls Hypertension Drug

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 25) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ...

  • GlobeNewswire2 months ago

    ContraVir Pharmaceuticals, Inc. Announces Pricing of $2.14 Million Public Offering

    ContraVir Pharmaceuticals, Inc. (“ContraVir,” the “Company,” “we,” “our” or “us”) (CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic viral infection, today announced the pricing of a public offering with expected total gross proceeds of approximately $2,140,000 before deducting placement agent fees and other offering expenses payable by the Company. Roth Capital Partners is acting as the lead placement agent for the offering. Brookline Capital Markets, a Division of CIM Securities, LLC is acting as co-placement agent for the offering.

  • GlobeNewswire2 months ago

    ContraVir Pharmaceuticals to Present CRV431 Phase 1 Data at the International Liver Congress™

    EDISON, N.J., April 11, 2019 -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of.

  • Again, Durham pharma loses a drug development partner
    American City Business Journals2 months ago

    Again, Durham pharma loses a drug development partner

    One of Chimerix's development and commercial partners is out, disclosing this week it would be terminating a four-year-old licensing agreement after deciding to drop Chimerix's drug – the second time in less than five years the drug has been abandoned.

  • GlobeNewswire3 months ago

    ContraVir Pharmaceuticals Announces Panel Participation at 31st Annual ROTH Conference

    ContraVir Pharmaceuticals, Inc. (CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic viral infection, today announced that it will participate in a panel at the 31st Annual ROTH Conference, being held in Laguna Niguel, California from March 17-19, 2019.

  • Benzinga5 months ago

    The Daily Biotech Pulse: Revance Common Stock Offering, Adcom Catalyst For Amgen

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech Stocks Hitting 52-week highs Jan. 15) Adial Pharmaceuticals Inc (NASDAQ: ADIL ) Avenue Therapeutics ...

  • GlobeNewswire5 months ago

    ContraVir Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders

    ContraVir Pharmaceuticals, Inc. (CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of liver disease arising from chronic viral infection and non-alcoholic steatohepatitis, announced today that its 2018 Annual Meeting of Stockholders scheduled to be held on January 15, 2019 (the “Annual Meeting”) was adjourned due to a lack of a quorum on the proposals to be approved. The Company intends to set a new record date and will add additional proposals to be voted on at the Annual Meeting. ContraVir is a biopharmaceutical company focused on the development and commercialization of targeted therapies for liver disease arising from chronic hepatitis B, C and D virus (HBV, HVC, HDV) and non-alcoholic steatohepatitis (NASH).

  • GlobeNewswire7 months ago

    ContraVir Pharmaceuticals to Present CRV431 Preclinical Data at the Anti-Fibrotic Drug Development Summit

    EDISON, N.J., Nov. 27, 2018 -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs.

  • GlobeNewswire7 months ago

    ContraVir Pharmaceuticals to Present Two Posters at The Liver Meeting® 2018, Hosted by the American Association for the Study of Liver Diseases

    EDISON, N.J., Nov. 06, 2018 -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs.

  • GlobeNewswire8 months ago

    Leading BioSciences Announces Appointments of James R. Neal and James Sapirstein to Board of Directors

    Leading BioSciences, a drug development company focused on improving human health through therapeutic protection of the Gastrobiome™, today announced the appointments of James R. Neal and James Sapirstein to its board of directors.  With more than three decades of life science industry experience each, Mr. Neal and Mr. Sapirstein provide Leading BioSciences with broad expertise in such areas as drug development and commercialization, strategic business operations, financial management and business development transactions. Mr. Neal, who currently serves as chief executive officer and board member for XOMA Corporation (XOMA), has nearly 35 years of life science industry leadership experience.  His expertise spans such areas as development and commercialization of novel technologies and products, as well as formation and oversight of successful global business and technology collaborations.  In his current role at XOMA, Mr. Neal spearheaded and secured the requisite capital to support a strategic transition of the company’s operations to focus on a royalty monetization model.  Prior to XOMA, Mr. Neal served as acting chief executive officer of Entelos, Inc, a leader in bio-simulation technologies, at which he was responsible for partnerships with global pharmaceutical companies such as Eli Lilly and GlaxoSmithKline.  He was chief executive officer at Iconix Biosciences at the time it was acquired by Entelos in 2007.  While at Iconix, Mr. Neal was credited with establishing multi-year collaborations with Bristol-Myers Squibb, Abbott Labs, Eli Lilly and the U.S. Food and Drug Administration.  He also previously served as executive vice president of Incyte Genomics, where he led the global commercial activities with pharmaceutical company collaborators and partners including Pfizer, Aventis and Schering-Plough, as well as sales, marketing and business development activities for the company.

  • GlobeNewswire8 months ago

    ContraVir Pharmaceuticals Completes Final Cohort Dosing in CRV431 Drug-Drug Interaction Study

    ContraVir Pharmaceuticals, Inc. (CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of hepatitis B virus (“HBV”), today announced that it has completed dosing of the last cohort of healthy subjects for its CRV431 drug-drug interaction (“DDI”) study. The single-dose crossover study evaluated subjects co-treated with Viread® (tenofovir disoproxil fumarate) (“TDF”), an approved treatment for chronic HBV infection. The DDI study is the second stage of CRV431's streamlined early clinical program, which is agreed upon with the U.S. Food and Drug Administration (“FDA”).